J&J gets a quick FDA OK for its block­buster pso­ri­a­sis con­tender guselkum­ab

Just four months af­ter rolling out its last batch of promis­ing late-stage da­ta, J&J has scored a quick OK for guselkum­ab as a new treat­ment for pso­ri­a­sis, one of the top drug prospects in the in­dus­try’s late-stage pipeline.

The IL-23 drug will now be com­mer­cial­ized as Trem­fya, says the phar­ma gi­ant, which tapped this drug as one of its most im­por­tant Phase III prod­ucts. To get the OK this fast, J&J says it used a pri­or­i­ty re­view vouch­er, an in­cen­tive that’s be­come a pricey com­mod­i­ty in the bio­phar­ma mar­ket as de­vel­op­ers turn to them for slash 4 months off the FDA’s re­view process.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER